Reviewing Evogene (EVGN) & The Competition

Evogene (NASDAQ:EVGN) is one of 844 public companies in the “Biotechnology” industry, but how does it weigh in compared to its peers? We will compare Evogene to related businesses based on the strength of its profitability, valuation, institutional ownership, earnings, dividends, risk and analyst recommendations.

Risk & Volatility

Evogene has a beta of 1.46, meaning that its stock price is 46% more volatile than the S&P 500. Comparatively, Evogene’s peers have a beta of 1.10, meaning that their average stock price is 10% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for Evogene and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evogene	1	0	0	0	1.00
Evogene Competitors	9789	15070	45344	1572	2.54

As a group, “Biotechnology” companies have a potential upside of 94.16%. Given Evogene’s peers stronger consensus rating and higher possible upside, analysts plainly believe Evogene has less favorable growth aspects than its peers.

Institutional and Insider Ownership

10.4% of Evogene shares are held by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are held by institutional investors. 7.4% of Evogene shares are held by company insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Evogene and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Evogene	-694.18%	-156.53%	-86.80%
Evogene Competitors	-9,046.59%	-199.78%	-30.61%

Earnings & Valuation

This table compares Evogene and its peers top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Evogene	$3.85 million	-$8.48 million	-0.39
Evogene Competitors	$691.12 million	$10.43 million	-10.13

Evogene’s peers have higher revenue and earnings than Evogene. Evogene is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Summary

Evogene peers beat Evogene on 9 of the 13 factors compared.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.